A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression

British Journal of Clinical Pharmacology
T M ItilS T Michael

Abstract

1 A double-blind placebo-controlled study of fluvoxamine and imipramine was performed in a group of depressed patients. Twenty-two patients received fluvoxamine (mean dose 101 mg/day), 25 received imipramine (mean dose 127 mg/day) and 22 received placebo. 2 Apart from an increase in the SGOT and SGPT values of four imipramine patients, no statistically significant changes in haematology or urinalysis were judged to be medically relevant. Fluvoxamine exhibited fewer anticholinergic side effects than imipramine. 3 Both fluvoxamine treated patients and imipramine-treated patients exhibited a statistically significant improvement at the end of the 28-day treatment period with respect to the placebo patients, as measured using the Hamilton Rating Scale for Depression, and the Clinical Global Impression Scale. Evaluations of the results of the Beck Depression Inventory and the Profile of Mood States revealed a statistically significant improvement for imipramine patients with respect to placebo at week 4, but not for fluvoxamine patients. It is postulated on the basis of quantitative pharmaco-EEG findings, that the slight superiority of imipramine over fluvoxamine was due to underdosing of the latter.

References

Aug 1, 1977·British Journal of Pharmacology·V ClaassenP Placheta
May 1, 1972·Archives of General Psychiatry·A CoppenR Noguera
Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton

❮ Previous
Next ❯

Citations

Jan 1, 1992·European Journal of Clinical Pharmacology·S R FlettC M Bradshaw
Jan 1, 1991·Biological Psychiatry·D J KupferA B McEachran
Jan 1, 1990·Progress in Neuro-psychopharmacology & Biological Psychiatry·D RothD V Sheehan
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan Undurraga, Ross J Baldessarini
Jan 1, 1985·Current Medical Research and Opinion·U A SiddiquiD K Jesinger
Oct 1, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mauricio P CunhaAna Lúcia S Rodrigues
May 1, 1991·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M AnsseauP Darimont
Nov 25, 2003·The Annals of Pharmacotherapy·Pieter StolkThomas R Einarson
Feb 18, 2005·International Journal of Geriatric Psychiatry·Maria Stella T GironBengt Winblad
Jul 20, 2007·The Cochrane Database of Systematic Reviews·J R GeddesJ Boynton
Feb 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M HotopfG Lewis
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Ichiro M OmoriToshi A Furukawa
May 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·D Hackett
Mar 13, 1993·BMJ : British Medical Journal·F SongJ Mason
Dec 1, 1990·The International Journal of Neuroscience·T Rammsayer, P Netter
Dec 1, 1993·The Annals of Pharmacotherapy·A DorevitchL Zilberman
Mar 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·J G EdwardsG L Pearce
Dec 19, 2013·Journal of Clinical Psychopharmacology·Bernadette SchurinkMartijn G H van Oijen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.